focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.21
Bid: 2.21
Ask: 2.29
Change: -0.045 (-1.96%)
Spread: 0.08 (3.62%)
Open: 2.35
High: 2.37
Low: 2.21
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
14 Sep 2022 12:46

IN BRIEF: ImmuPharma receives response for FDA for Lupuzor

ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug's clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome.

Read more
7 Sep 2022 09:55

ImmuPharma raises GBP150,000 via issue of 3 million new shares

ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital.

Read more
31 Aug 2022 21:41

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Aug 2022 19:08

IN BRIEF: ImmuPharma raises GBP950,000 from broker option

ImmuPharma PLC - specialist drug discovery and development company - Raises GBP950,000 under broker option, taking total proceeds from placing and broker option to GBP1.04 million. "Further to the announcement of August 3, 2022, the directors confirm that the fundraising, together with existing funding and funding arrangements, will provide the company with sufficient working capital for at least the next 12 months," it says.

Read more
3 Aug 2022 19:40

IN BRIEF: ImmuPharma to raise funds for investment into pipeline

ImmuPharma PLC - specialist drug discovery and development company - Intends to raise GBP1.1 million through the placing and subscription of 21.8 million shares at a price of 5.0 pence per share.

Read more
7 Jul 2022 20:35

IN BRIEF: ImmuPharma US partner gets Type C meeting with US FDA

ImmuPharma PLC - specialist drug discovery and development company - Says Avion Pharmaceuticals, its US partner for its Lupuzor lupus treatment, received a Type C Meeting confirmation from the US Food & Drug Administration. The London-listed company says statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by August 29.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 16:53

IN BRIEF: ImmuPharma shares fall as annual loss widens

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to GBP8.9 million in 2021 from GBP7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to GBP118,350 from GBP126,667. Research and development expenses surge to GBP3.7 million from GBP2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.

Read more
6 May 2022 19:11

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
4 May 2022 13:03

ImmuPharma making final preparations for Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.

Read more
13 Apr 2022 13:54

ImmuPharma surges on success in latest trial of lupus treatment

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised international third phase trial in lupus patients.

Read more
13 Apr 2022 12:09

IN BRIEF: Immupharma shares soar on positive data from lupus study

Immupharma PLC - London-based drug discovery and development company - Says its Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, has met the key endpoints requested. The study is part of an international phase 3 trial of the Lupuzor treatment for patients with lupus disease. The dosing of healthy subjects started on February 15 and showed that P140 was safe and well-tolerated across all doses and in all subjects. Notes that the positive data now clears the path for the start of all clinical studies within the P140 platform. Adds that there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder.

Read more
13 Apr 2022 11:06

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Feb 2022 18:29

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Read more
7 Feb 2022 13:13

ImmuPharma updates plan for trials of lupus treatment Lupuzor

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.